DOCSLIB.ORG

Sphingolipidoses

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

J Clin Pathol: first published as 10.1136/jcp.27.Suppl_8.94 on 1 January 1974. Downloaded from J. clini. Path., 27, Suppl. (Roy. Coll. Path.), 8, 94-105 Sphingolipidoses KONRAD SANDHOFF From the Max-Planck Institute for Psychiatry, Neurochemische Abteilung, Muntich, Gernmany Sphingolipidoses are inborn errors of metabolism, 1882; Sachs, 1896; Fabry, 1898; Anderson, 1898; characterized by the accumulation of sphingo- Alzheimer, 1910; Niemann, 1914; Krabbe, 1916; lipids. These lysosomal diseases (Hers, 1965) are due Scholz, 1925). With progress in the analysis of lipids to a deficiency in the degradative pathway (for these diseases have been more accurately defined as references see Hers and Van Hoof, 1973). So far, specific lipid storage diseases, and it has become neither changes in the extent of sphingolipid bio- feasible to classify them more systematically on the synthesis, ie, an overproduction, nor a deficiency basis of the main accumulating lipid (Aghion, 1934; of a transferase activity have been observed. The Klenk, 1934, 1942; Jatzkewitz, 1958; Svennerholm, latter could result in the absence of the enzyme 1962). However, these nomenclatures, the first product and/or accumulation of its substrates. based on clinical and pathomorphological descrip- Recessive inherited deficiencies of sphingolipid tions and the second based on the main accumulating degrading enzyme activities have been found in all lipid, are not always congruent. For example, tissues that have been tested. The sphingolipid diseases such as infantile GM2-gangliosidosis (Tay- hydrolases studied thus far have been shown to be of Sachs disease) are ganglioside storage diseases, lysosomal origin (for references, see Vaes, 1973). while no ganglioside accumulation has been found Most of these enzymes display an optimal activity in neuronal ceroid-lipofuscinoses (Batten-Vogt dis- in an acidic pH range. With the remarkable exception ease), even though these diseases have been classified copyright. of Krabbe's disease, the storage material is found in in the same group of familial amaurotic idiocies vacuoles or storage granules which represent pro- (for references, see Zeman and Siakotos, 1973). foundly modified lysosomes incapable of degrading Different biochemical defects can therefore result the accumulating lipids (fig 1; for references, see in a similar clinical and pathological picture. Hers, 1973). Some of these storage granules, eg, the Furthermore, biochemical analysis has shown that membranous cytoplasmic bodies in Tay-Sachs infantile amaurotic idiocy (Tay-Sachs disease), disease, have been shown to contain lysosomal-like defined by clinical and pathomorphological criteria, enzymatic activities (Tallman, Brady, and Suzuki, includes at least two closely related but nevertheless 1971). The amount of stored material is highest in biochemically different diseases: the variants 0 and http://jcp.bmj.com/ tissues which exhibit the greatest biosynthetic rates B of infantile GM2-gangliosidosis (Sandhoff, Harzer, for the accumulated lipids. The pathogenesis of this Wassle, and Jatzkewitz, 1971). process seems to be especially severe when the ner- The classification of the sphingolipidoses based vous tissue is involved. on the accumulation of lipid appears to be more The physiological role of sphingolipids is still precise than the one based on clinical and patho- poorly understood, and almost no knowledge exists morphological criteria but is also unsatisfactory. about the mechanism by which the lipid accumula- In many of these diseases, several lipids accumulate on September 28, 2021 by guest. Protected tion finally causes dysfunction and death of the simultaneously, often concomitant with the accumu- affected cells. It seems obvious, however, that an lation of polysaccharides, as in GM1-gangliosidosis elevated concentration of a single sphingolipid (for references, see Van Hoof, 1973). The main reason may cause a variety of changes in the cells, including for this is believed to be the broad substrate speci- changes in incorporation of lipid into membranes ficity of certain sphingolipid hydrolases. Many of as well as mechanical distortion of the cell due to the these enzymes catalyze the breakdown of several deposition of the storage compound in granules and substances that have one chemical feature in com- vacuoles (fig 1) which finally may occupy an abnorm- mon, and the deficiency of such an enzyme can ally large portion of the cytoplasm. easily result in the accumulation of several com- pounds. Therefore, the enzymatic deficiencies should Nomenclature be characterized in order to obtain a final classifica- As clinical entities, many of these diseases have long tion of the storage diseases based on primary meta- been known by eponyms (Tay, 1881; Gauchei, bolic defects. 94 J Clin Pathol: first published as 10.1136/jcp.27.Suppl_8.94 on 1 January 1974. Downloaded from Sphinigolipidoses 95 IN < .; t^--* o.. i . - AK F.7 .. k ..%:.-.t ::oj i...e; mS,:.w+' '''_f;; -,.1 C9<>);h g a. .\ ., S. *: ...,.... {. * w> XJ t> tz._.Saiw.S \. 4. Wk !!. .. - **e.:'2.-w;._:.:.w :ki copyright. .... ON http://jcp.bmj.com/ I L .% on September 28, 2021 by guest. Protected t-eR i% = Fig 1 Neurone from cortex ofa child with Tay-Sachs disease. Tightly packed membranous cytoplasmic bodies (MCB) x 56 000 (electron micrograph; courtesy of B. W. Volk, Isaac Albert Research Institute of the Kingsbrook Jewish Medical Center; New York). J Clin Pathol: first published as 10.1136/jcp.27.Suppl_8.94 on 1 January 1974. Downloaded from 96 Sandhoff 0 HN ~^ - HOCH2 4 OH Ceram id* W'/NW Gal - GaINAc-Gal GIc Ceramide Neu Ac copyright. Ganglioside GM, Fig 2 Structure ofceramide and ganglioside GM1. GA1, asialoganglioside GM1; GA2, asialoganglioside GM2; Cer, ceramide (= N-acyl-sphingosine); FA, fatty acid; Gal, D-galactose; GalNAc, N-acetyl-D-galactosamine, GM1, ganglioside GM1; GM2, ganglioside GM2; Glc, D-glucose; NeuAc, N-acetylneuraminic acid; sialic acid, N-acylneuraminic acid; Sph, sphingosine. Catabolism of Sphingolipids and Enzyme Deficiencies oligosialo-gangliosides or of ganglioside GM3 (fig 3), http://jcp.bmj.com/ in Sphingolipidoses has never been observed. It may be that a neuramini- dase deficiency is incompatible with life and there- Sphingolipids have in common a hydrophobic fore lethal at very early stages of development. ceramide (ceramide = N-acylsphingosine) residue bound to either a hydrophilic mono- or oligo- saccharide chain (fig 2), or in the case of sphingo- Variant Forms of Sphingolipidoses myelin, phosphorylcholine. Figure 3 shows schem- atically the degradative pathway of sphingolipids. The schematic representation of sphingolipidoses on September 28, 2021 by guest. Protected The degradation always starts from the hydrophilic given in figure 3 is complicated by the fact end of the molecule (for references, see Gatt and that many sphingolipid storage diseases exist as Bahrenholz, 1973; Leeden and Yu, 1973; Sugita, variant forms. Analysis of the enzymes involved in Dulaney, and Moser, 1972). Each step is catalyzed the breakdown of sphingolipids has shown that by a lysosomal hydrolase that removes the terminal many of them occur as multiple forms, or iso- non-reducing sugar moiety in the case of ceramide enzymes, of which one or more can be deficient in oligosaccharides, sulphate in the case of sulphatides, different forms of a lipid storage disease. A further or phosphorylcholine in the case of sphingomyelin. heterogeneity seems to be due to the fact that dif- It is of special interest to note that there is a disease ferent degrees of enzyme deficiency have been known for each degradation step in which the respect- observed in different families affected with a given ive hydrolase activity is deficient (fig 3), with one storage disease. Patients with higher residual important exception: a neuraminidase deficiency, enzymatic activity appear to have a longer life span which should result in a primary accumulation of than those with almost complete enzyme deficiency. J Clin Pathol: first published as 10.1136/jcp.27.Suppl_8.94 on 1 January 1974. Downloaded from Sphingolipidoses 97 Oligosialogangliosides Gal "INAc- al-Glc -Cer ----oGl-GlAc -G -Glc -Cer (GM1) (GAS) C INAc -Gal-Gal-CGlc -Ce r Ga lNAc-Gal-Glc -Ce r GalNAc -Gal1-Glc -Cer (globoside) (G ) I (0,2) * 10 9,10 10 Fig 3 Catabolism ofsphingolipids and enzyme Gal-G-Glc-Cer Ga1 -Cer deficiencies in sphingolipidoses. Abbreviations as in figure 2. Gal1-Glc+8+-Cer GJ1al-Ga-Cer Phosphory lcholine -Ce r Glc -Cer Gal1-Cer+Gal1-Cer ( sphingoye lin) I8 cceebros ide ) 56(sulph.at ide ) +3 > ~~~~~~5,6 Cer5md e Sp + FA Number Disease Major Storage Compound Deficient Enzyme Activity 1 Farber's disease (ceramidosis) Ceramide Ceramidase 2 Niemann-Pick disease Sphingomyelin Sphingomyelinase (sphingomyelinosis) 3 Gaucher's disease Glucocerebroside Glucocerebroside ,-glucosidase (glucocerebrosidosis) copyright. 4 Krabbe's disease Galactocerebroside Galactocerebroside ,B-galactosidase (galactocerebrosidosis) 5 Metachromatic leucodystrophy Cerebrosidesulphates Cerebrosidesulphatase, (sulphatidosis, 'variant B') (arylsulphatase A) 6 Metachromatic leucodystrophy Cerebrosidesulphatases and steroid Arylsulphatases A, B, C and steroid (sulphatidosis, 'Variant 0') sulphates 7 Lactosylceramidosis Lactosylceramide Lactosylceramide B-galactosidase 8 Fabry's disease (a-galactosyl- a-Galactosyl-lactosylceramide a-Galactosidase lactosyl-ceramidosis) 9 Tay-Sachs disease (GM2- Ganglioside GM2 N-Acetyl-g-D-hexosaminidase A gangliosidosis, variant B1) http://jcp.bmj.com/
Recommended publications
  • Implications in Parkinson's Disease

    Implications in Parkinson's Disease

    Journal of Clinical Medicine Review Lysosomal Ceramide Metabolism Disorders: Implications in Parkinson’s Disease Silvia Paciotti 1,2 , Elisabetta Albi 3 , Lucilla Parnetti 1 and Tommaso Beccari 3,* 1 Laboratory of Clinical Neurochemistry, Department of Medicine, University of Perugia, Sant’Andrea delle Fratte, 06132 Perugia, Italy; [email protected] (S.P.); [email protected] (L.P.) 2 Section of Physiology and Biochemistry, Department of Experimental Medicine, University of Perugia, Sant’Andrea delle Fratte, 06132 Perugia, Italy 3 Department of Pharmaceutical Sciences, University of Perugia, Via Fabretti, 06123 Perugia, Italy; [email protected] * Correspondence: [email protected] Received: 29 January 2020; Accepted: 20 February 2020; Published: 21 February 2020 Abstract: Ceramides are a family of bioactive lipids belonging to the class of sphingolipids. Sphingolipidoses are a group of inherited genetic diseases characterized by the unmetabolized sphingolipids and the consequent reduction of ceramide pool in lysosomes. Sphingolipidoses include several disorders as Sandhoff disease, Fabry disease, Gaucher disease, metachromatic leukodystrophy, Krabbe disease, Niemann Pick disease, Farber disease, and GM2 gangliosidosis. In sphingolipidosis, lysosomal lipid storage occurs in both the central nervous system and visceral tissues, and central nervous system pathology is a common hallmark for all of them. Parkinson’s disease, the most common neurodegenerative movement disorder, is characterized by the accumulation and aggregation of misfolded α-synuclein that seem associated to some lysosomal disorders, in particular Gaucher disease. This review provides evidence into the role of ceramide metabolism in the pathophysiology of lysosomes, highlighting the more recent findings on its involvement in Parkinson’s disease. Keywords: ceramide metabolism; Parkinson’s disease; α-synuclein; GBA; GLA; HEX A-B; GALC; ASAH1; SMPD1; ARSA * Correspondence [email protected] 1.
  • Sphingolipid Metabolism Diseases ⁎ Thomas Kolter, Konrad Sandhoff

    Sphingolipid Metabolism Diseases ⁎ Thomas Kolter, Konrad Sandhoff

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Biochimica et Biophysica Acta 1758 (2006) 2057–2079 www.elsevier.com/locate/bbamem Review Sphingolipid metabolism diseases ⁎ Thomas Kolter, Konrad Sandhoff Kekulé-Institut für Organische Chemie und Biochemie der Universität, Gerhard-Domagk-Str. 1, D-53121 Bonn, Germany Received 23 December 2005; received in revised form 26 April 2006; accepted 23 May 2006 Available online 14 June 2006 Abstract Human diseases caused by alterations in the metabolism of sphingolipids or glycosphingolipids are mainly disorders of the degradation of these compounds. The sphingolipidoses are a group of monogenic inherited diseases caused by defects in the system of lysosomal sphingolipid degradation, with subsequent accumulation of non-degradable storage material in one or more organs. Most sphingolipidoses are associated with high mortality. Both, the ratio of substrate influx into the lysosomes and the reduced degradative capacity can be addressed by therapeutic approaches. In addition to symptomatic treatments, the current strategies for restoration of the reduced substrate degradation within the lysosome are enzyme replacement therapy (ERT), cell-mediated therapy (CMT) including bone marrow transplantation (BMT) and cell-mediated “cross correction”, gene therapy, and enzyme-enhancement therapy with chemical chaperones. The reduction of substrate influx into the lysosomes can be achieved by substrate reduction therapy. Patients suffering from the attenuated form (type 1) of Gaucher disease and from Fabry disease have been successfully treated with ERT. © 2006 Elsevier B.V. All rights reserved. Keywords: Ceramide; Lysosomal storage disease; Saposin; Sphingolipidose Contents 1. Sphingolipid structure, function and biosynthesis ..........................................2058 1.1.
  • Management of Patients with Cardiac Manifestations

    Management of Patients with Cardiac Manifestations

    MANAGEMENT OF PATIENTS WITH CARDIAC MANIFESTATIONS KDIGOAleš Linhart First School of Medicine Charles University Prague Czech Republic Disclosure of Interests Speaker´s honoraria, travel reimbursements and consultancy honoraria from: • Genzyme • Shire HGT • Amicus Therapeutics • Actelion KDIGO KDIGO Controversies Conference on Fabry Disease | October 15-17, 2015 | Dublin, Ireland KDIGO HEART FAILURE KDIGO Controversies Conference on Fabry Disease | October 15-17, 2015 | Dublin, Ireland Diffuse LVH on MRI in Fabry disease KDIGO KDIGO Controversies Conference on Fabry Disease | October 15-17, 2015 | Dublin, Ireland Data source: General University Hospital, Prague Cardiac symptoms in AFD LV hypertrophy absent LV hypertrophy present KDIGO KDIGO Controversies Conference on Fabry Disease | October 15-17, 2015 | Dublin, Ireland Linhart et al., European Heart Journal 2007 28(10):1228-1235 Fabry left ventricular function KDIGO KDIGO Controversies Conference on Fabry Disease | October 15-17, 2015 | Dublin, Ireland N-Terminal Pro-BNP in Diagnosis of Cardiac Involvement in AFD Patients 117 patients, (age 48 ± 15 years, 46.2% men) - BNP elevated in 57% KDIGO KDIGO Controversies Conference on Fabry Disease | October 15-17, 2015 | Dublin, Ireland Coats et al., Am J Cardiol. 2013;111:111-7. Diagnosis of heart failure KDIGO ESC GuidelinesKDIGO Controversies for the Conference diagnosis on Fabry and Disease treatment | October of 15-17, acute 2015 and | Dublin, chronic Ireland heart failure 2012. European Heart Journal 2012; 33: 1787–1847 Trials in heart failure with preserved ejection fraction DIG-PEF Digoxin Trend to ↓ hospitalizations ↑ UAP CHARM-PRESERVED Candesartan Trend ↓ hospitalizations I-PRESERVE Irbesartan No effect PEP-CHF PerindoprilKDIGO↓ hospitalizations SENIORS HF-PEF Nebivolol Trend to ↓ Clinical subgroup complications TOP-CAT Spironolactone Effective in subjects recruited in USA and LATAM KDIGO Controversies Conference on Fabry Disease | October 15-17, 2015 | Dublin, Ireland J Am Coll Cardiol.
  • Understanding the Molecular Pathobiology of Acid Ceramidase Deficiency

    Understanding the Molecular Pathobiology of Acid Ceramidase Deficiency

    Understanding the Molecular Pathobiology of Acid Ceramidase Deficiency By Fabian Yu A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Institute of Medical Science University of Toronto © Copyright by Fabian PS Yu 2018 Understanding the Molecular Pathobiology of Acid Ceramidase Deficiency Fabian Yu Doctor of Philosophy Institute of Medical Science University of Toronto 2018 Abstract Farber disease (FD) is a devastating Lysosomal Storage Disorder (LSD) caused by mutations in ASAH1, resulting in acid ceramidase (ACDase) deficiency. ACDase deficiency manifests along a broad spectrum but in its classical form patients die during early childhood. Due to the scarcity of cases FD has largely been understudied. To circumvent this, our lab previously generated a mouse model that recapitulates FD. In some case reports, patients have shown signs of visceral involvement, retinopathy and respiratory distress that may lead to death. Beyond superficial descriptions in case reports, there have been no in-depth studies performed to address these conditions. To improve the understanding of FD and gain insights for evaluating future therapies, we performed comprehensive studies on the ACDase deficient mouse. In the visual system, we reported presence of progressive uveitis. Further tests revealed cellular infiltration, lipid buildup and extensive retinal pathology. Mice developed retinal dysplasia, impaired retinal response and decreased visual acuity. Within the pulmonary system, lung function tests revealed a decrease in lung compliance. Mice developed chronic lung injury that was contributed by cellular recruitment, and vascular leakage. Additionally, we report impairment to lipid homeostasis in the lungs. ii To understand the liver involvement in FD, we characterized the pathology and performed transcriptome analysis to identify gene and pathway changes.
  • Genetic Ablation of Acid Ceramidase in Krabbe Disease Confirms the Psychosine Hypothesis and Identifies a New Therapeutic Target

    Genetic Ablation of Acid Ceramidase in Krabbe Disease Confirms the Psychosine Hypothesis and Identifies a New Therapeutic Target

    Genetic ablation of acid ceramidase in Krabbe disease confirms the psychosine hypothesis and identifies a new therapeutic target Yedda Lia, Yue Xub, Bruno A. Beniteza, Murtaza S. Nagreec, Joshua T. Dearborna, Xuntian Jianga, Miguel A. Guzmand, Josh C. Woloszynekb, Alex Giaramitab, Bryan K. Yipb, Joseph Elsberndb, Michael C. Babcockb, Melanie Lob, Stephen C. Fowlere, David F. Wozniakf, Carole A. Voglerd, Jeffrey A. Medinc,g, Brett E. Crawfordb, and Mark S. Sandsa,h,1 aDepartment of Medicine, Washington University School of Medicine, St. Louis, MO 63110; bDepartment of Research, BioMarin Pharmaceutical Inc., Novato, CA 94949; cDepartment of Medical Biophysics, University of Toronto, Toronto, ON M5S, Canada; dDepartment of Pathology, St. Louis University School of Medicine, St. Louis, MO 63104; eDepartment of Pharmacology and Toxicology, University of Kansas, Lawrence, KS 66045; fDepartment of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110; gPediatrics and Biochemistry, Medical College of Wisconsin, Milwaukee, WI 53226; and hDepartment of Genetics, Washington University School of Medicine, St. Louis, MO 63110 Edited by William S. Sly, Saint Louis University School of Medicine, St. Louis, MO, and approved August 16, 2019 (received for review July 15, 2019) Infantile globoid cell leukodystrophy (GLD, Krabbe disease) is a generated catabolically through the deacylation of galactosylceramide fatal demyelinating disorder caused by a deficiency in the lyso- by acid ceramidase (ACDase). This effectively dissociates GALC somal enzyme galactosylceramidase (GALC). GALC deficiency leads deficiency from psychosine accumulation, allowing us to test the to the accumulation of the cytotoxic glycolipid, galactosylsphingosine long-standing psychosine hypothesis. We demonstrate that genetic (psychosine). Complementary evidence suggested that psychosine loss of ACDase activity [Farber disease (FD) (8)] in the twitcher is synthesized via an anabolic pathway.
  • The Multiple Roles of Sphingomyelin in Parkinson's Disease

    The Multiple Roles of Sphingomyelin in Parkinson's Disease

    biomolecules Review The Multiple Roles of Sphingomyelin in Parkinson’s Disease Paola Signorelli 1 , Carmela Conte 2 and Elisabetta Albi 2,* 1 Biochemistry and Molecular Biology Laboratory, Health Sciences Department, University of Milan, 20142 Milan, Italy; [email protected] 2 Department of Pharmaceutical Sciences, University of Perugia, 06126 Perugia, Italy; [email protected] * Correspondence: [email protected] Abstract: Advances over the past decade have improved our understanding of the role of sphin- golipid in the onset and progression of Parkinson’s disease. Much attention has been paid to ceramide derived molecules, especially glucocerebroside, and little on sphingomyelin, a critical molecule for brain physiopathology. Sphingomyelin has been proposed to be involved in PD due to its presence in the myelin sheath and for its role in nerve impulse transmission, in presynaptic plasticity, and in neurotransmitter receptor localization. The analysis of sphingomyelin-metabolizing enzymes, the development of specific inhibitors, and advanced mass spectrometry have all provided insight into the signaling mechanisms of sphingomyelin and its implications in Parkinson’s disease. This review describes in vitro and in vivo studies with often conflicting results. We focus on the synthesis and degradation enzymes of sphingomyelin, highlighting the genetic risks and the molecular alterations associated with Parkinson’s disease. Keywords: sphingomyelin; sphingolipids; Parkinson’s disease; neurodegeneration Citation: Signorelli, P.; Conte, C.; 1. Introduction Albi, E. The Multiple Roles of Sphingomyelin in Parkinson’s Parkinson’s disease (PD) is the second most common neurodegenerative disease (ND) Disease. Biomolecules 2021, 11, 1311. after Alzheimer’s disease (AD). Recent breakthroughs in our knowledge of the molecular https://doi.org/10.3390/ mechanisms underlying PD involve unfolded protein responses and protein aggregation.
  • Disease Reference Book

    Disease Reference Book

    The Counsyl Foresight™ Carrier Screen 180 Kimball Way | South San Francisco, CA 94080 www.counsyl.com | [email protected] | (888) COUNSYL The Counsyl Foresight Carrier Screen - Disease Reference Book 11-beta-hydroxylase-deficient Congenital Adrenal Hyperplasia .................................................................................................................................................................................... 8 21-hydroxylase-deficient Congenital Adrenal Hyperplasia ...........................................................................................................................................................................................10 6-pyruvoyl-tetrahydropterin Synthase Deficiency ..........................................................................................................................................................................................................12 ABCC8-related Hyperinsulinism........................................................................................................................................................................................................................................ 14 Adenosine Deaminase Deficiency .................................................................................................................................................................................................................................... 16 Alpha Thalassemia.............................................................................................................................................................................................................................................................
  • The Metabolism of Tay-Sachs Ganglioside: Catabolic Studies with Lysosomal Enzymes from Normal and Tay-Sachs Brain Tissue

    The Metabolism of Tay-Sachs Ganglioside: Catabolic Studies with Lysosomal Enzymes from Normal and Tay-Sachs Brain Tissue

    The Metabolism of Tay-Sachs Ganglioside: Catabolic Studies with Lysosomal Enzymes from Normal and Tay-Sachs Brain Tissue JOHN F. TALLMAN, WILLIAM G. JOHNSON, and ROSCOE 0. BRADY From the Developmental and Metabolic Neurology Branch, National Institute of Neurological Diseases and Stroke, National Institutes of Health, Bethesda, Maryland 20014, and the Department of Biochemistry, Georgetown University School of Medicine, Washington, D. C. 20007 A B S T R A C T The catabolism of Tay-Sachs ganglioside, date fronm the 19th century and over 599 cases have been N-acetylgalactosaminyl- (N-acetylneuraminosyl) -galac- reported (1). Onset of the disease is in the first 6 months tosylglucosylceramide, has been studied in lysosomal of life and is characterized by apathy, hyperacusis, motor preparations from normal human brain and brain ob- weakness, and appearance of a macular cherry-red spot tained at biopsy from Tay-Sachs patients. Utilizing Tay- in the retina. Seizures and progressive mental deteriora- Sachs ganglioside labeled with '4C in the N-acetylgalac- tion follow with blindness, deafness, and spasticity, lead- tosaminyl portion or 3H in the N-acetylneuraminosyl ing to a state of decerebrate rigidity. These infants usu- portion, the catabolism of Tay-Sachs ganglioside may be ally die by 3 yr of age (2). initiated by either the removal of the molecule of A change in the chemical composition of the brain of N-acetylgalactosamine or N-acetylneuraminic acid. The such patients was first detected by Klenk who showed activity of the N-acetylgalactosamine-cleaving enzyme that there was an increase in the ganglioside content (hexosaminidase) is drastically diminished in such compared with normal human brain tissue (3).
  • GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies

    GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies

    International Journal of Molecular Sciences Review GM2 Gangliosidoses: Clinical Features, Pathophysiological Aspects, and Current Therapies Andrés Felipe Leal 1 , Eliana Benincore-Flórez 1, Daniela Solano-Galarza 1, Rafael Guillermo Garzón Jaramillo 1 , Olga Yaneth Echeverri-Peña 1, Diego A. Suarez 1,2, Carlos Javier Alméciga-Díaz 1,* and Angela Johana Espejo-Mojica 1,* 1 Institute for the Study of Inborn Errors of Metabolism, Faculty of Science, Pontificia Universidad Javeriana, Bogotá 110231, Colombia; [email protected] (A.F.L.); [email protected] (E.B.-F.); [email protected] (D.S.-G.); [email protected] (R.G.G.J.); [email protected] (O.Y.E.-P.); [email protected] (D.A.S.) 2 Faculty of Medicine, Universidad Nacional de Colombia, Bogotá 110231, Colombia * Correspondence: [email protected] (C.J.A.-D.); [email protected] (A.J.E.-M.); Tel.: +57-1-3208320 (ext. 4140) (C.J.A.-D.); +57-1-3208320 (ext. 4099) (A.J.E.-M.) Received: 6 July 2020; Accepted: 7 August 2020; Published: 27 August 2020 Abstract: GM2 gangliosidoses are a group of pathologies characterized by GM2 ganglioside accumulation into the lysosome due to mutations on the genes encoding for the β-hexosaminidases subunits or the GM2 activator protein. Three GM2 gangliosidoses have been described: Tay–Sachs disease, Sandhoff disease, and the AB variant. Central nervous system dysfunction is the main characteristic of GM2 gangliosidoses patients that include neurodevelopment alterations, neuroinflammation, and neuronal apoptosis. Currently, there is not approved therapy for GM2 gangliosidoses, but different therapeutic strategies have been studied including hematopoietic stem cell transplantation, enzyme replacement therapy, substrate reduction therapy, pharmacological chaperones, and gene therapy.
  • Hyperglycopeptiduria in Genetic Mucolipidoses

    Hyperglycopeptiduria in Genetic Mucolipidoses

    Tohoku J. exp. Med., 1974, 112, 373-380 Hyperglycopeptiduria in Genetic Mucolipidoses TADAO ORII, TAKAMICHI CHIBA, RYOJI MINAMI, KAZUKO S UKEGAWA and TooRu NAKAO Department of Pediatrics, Sapporo Medical College, Sapporo ORII, T., CHmA, T., MINAMI, R., SUKEUAWA,K. and NAKAO, T. Hyper glycopeptiduria in Genetic Mucolipidoses. Tohoku J. exp. Med., 1974, 112 (4), 373-380 -Urinary cetylpyridinium chloride (CPC)-precipitates and non-CPC- precipitates in normal male children and seven patients with a new type of mucolipidosis, GM1-gangliosidosis type 1, I-cell disease, Hurler syndrome, Morquio syndrome, Gaucher's disease adult type and Tay-Sachs disease were studied using several methods including Sephadex G-25 gel filtration, ECTEOLA-cellulose column chromatography and enzymatic digestion with chondroitinase ABC. 1) Considerable amounts of glycopeptide fractions were detected in the urine of the patients with a new type of mucolipidosis, Gm1-gangliosidosis type 1, I-cell disease and also Gaucher's disease adult type compared with that of normal male children and other patients. 2) The total acid mucopolysaccharides excreted into the urine from two patients with Hurler syndrome and Morquio syndrome were much higher than those excreted in normal male children and other patients. 3) Large amounts of the chondroitinase ABC-resistant acid mucopolysaccharides were found in the urine of patients with Hurler syndrome, Morquio syndrome and Gm,-gangliosidosis type 1. mucolipidoses; glycopeptiduria; Gaucher's disease A group of storage disease which exhibits signs and symptoms of both mucopolysaccharidoses and sphingolipidoses has tentatively been classified as the mucolipidoses by Spranger and Wiedemann (1970). With the exception of the Austin type of sulfatidosis, it has been reported by several workers that the patients with mucolipidosis generally show normal urinary excretion of uronic acid-containing mucopolysaccharides.
  • Farber Lipogranulomatosis

    Farber Lipogranulomatosis

    Farber lipogranulomatosis Description Farber lipogranulomatosis is a rare inherited condition involving the breakdown and use of fats in the body (lipid metabolism). In affected individuals, lipids accumulate abnormally in cells and tissues throughout the body, particularly around the joints. Three classic signs occur in Farber lipogranulomatosis: a hoarse voice or a weak cry, small lumps of fat under the skin and in other tissues (lipogranulomas), and swollen and painful joints. Affected individuals may also have difficulty breathing, an enlarged liver and spleen (hepatosplenomegaly), and developmental delay. Researchers have described seven types of Farber lipogranulomatosis based on their characteristic features. Type 1 is the most common, or classical, form of this condition and is associated with the classic signs of voice, skin, and joint problems that begin a few months after birth. Developmental delay and lung disease also commonly occur. Infants born with type 1 Farber lipogranulomatosis usually survive only into early childhood. Types 2 and 3 generally have less severe signs and symptoms than the other types. Affected individuals have the three classic signs and usually do not have developmental delay. Children with these types of Farber lipogranulomatosis typically live into mid- to late childhood. Types 4 and 5 are associated with severe neurological problems. Type 4 usually causes life-threatening health problems beginning in infancy due to massive lipid deposits in the liver, spleen, lungs, and immune system tissues. Children with this type typically do not survive past their first year of life. Type 5 is characterized by progressive decline in brain and spinal cord (central nervous system) function, which causes paralysis of the arms and legs (quadriplegia), seizures, loss of speech, involuntary muscle jerks ( myoclonus), and developmental delay.
  • Correction of the Enzymic Defect in Cultured Fibroblasts from Patients with Fabry's Disease: Treatment with Purified A-Galactosidase from Ficin

    Correction of the Enzymic Defect in Cultured Fibroblasts from Patients with Fabry's Disease: Treatment with Purified A-Galactosidase from Ficin

    Pediat. Res. 7: 684-690 (1973) Fabry's disease genetic disease ficin trihexosylceramide a-galactosidase Correction of the Enzymic Defect in Cultured Fibroblasts from Patients with Fabry's Disease: Treatment with Purified a-Galactosidase from Ficin GLYN DAWSON1341, REUBEN MATALON, AND YU-TEH LI Departments of Pediatrics and Biochemistry, Joseph P. Kennedy, Jr., Mental Retardation Research Center, University of Chicago, Chicago, Illinois, USA Extract Cultured skin fibroblasts from patients with Fabry's disease showed the characteristic a-galactosidase deficiency and accumulated a four- to sixfold excess of trihexosylceram- ide (GL-3). To demonstrate the correction, cells previously labeled with U-14G-glucose were grown in medium containing a purified a-galactosidase preparation obtained from ficin. The results demonstrated that a-galactosidase was taken up rapidly from the medium and that, despite its apparent instability in the fibroblasts, it was able to become incorporated into lysosomes and catabolize the stored trihexosylceramide. These findings support the reports of therapeutic endeavors by renal transplantation and plasma infusion in Fabry's disease and suggest the extension of such studies to other related disorders in which the cultured skin fibroblasts are chemically abnormal, namely, Gaucher's disease, lactosylceramidosis, and GM2-gangliosidosis type II. Speculation It may be possible to replace the specific missing lysosomal hydrolase in various sphingolipidoses and other storage diseases. Although we do not propose to effect enzyme replacement therapy in vivo with a plant enzyme, such studies in tissue culture are valid, and eventually human a-galactosidase, of comparable activity and purity, will become available. Introduction tially unaffected, periodic crises of pain occur and this may be explained by the accumulation of GL-3 in the Fabry's disease (angiokeratoma corporis diffusum uni- dorsal root ganglia [21, 23].